Enoticumab (REGN421) is an anti-DLL4 mAb that displayed modest anti-tumor activity in phase I clinical trials (NCT00871559) for patients with solid tumors, with 50% of patients having SD, and 2 out of 32 achieving PR [373]. The gene discussed is DLL4; the disease is neoplasm.